SONOSINE LIMITED

Active Begbroke

Research and experimental development on biotechnology

4 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
S

SONOSINE LIMITED

Research and experimental development on biotechnology

Founded 26 Aug 2015 Active Begbroke, England 4 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology

Previous Company Names

OXFORD ENHANCED MEDICAL LIMITED 26 Aug 2015 — 20 Jan 2021
Accounts Due 30 Sept 2026 3 months remaining
Confirmation Submitted 14 Apr 2026 Next due 28 Apr 2027 10 months remaining
Net assets £-197K £319K 2024 year on year
Total assets £105K £50K 2024 year on year
Total Liabilities £303K £269K 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

The Centre Of Innovation And Enterprise Oxford University Begbroke Science Park Begbroke Hill, Woodstock Road Begbroke OX5 1PF England

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for SONOSINE LIMITED (09750828), an active life sciences and medical technology company based in Begbroke, England. Incorporated 26 Aug 2015. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type total-exemption-full
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Net Assets, Total Assets & Total Liabilities (2016–2024)

Cash in Bank

£13.50k

Decreased by £23.12k (-63%)

Net Assets

-£197.39k

Decreased by £319.12k (-262%)

Total Liabilities

£302.52k

Increased by £269.02k (+803%)

Turnover

N/A

Employees

4

Debt Ratio

288%

Increased by 266 (+1209%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

8 Allotments 78,813 Shares £2.03m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
3 Mar 202619,673£220k£11.17
25 Apr 202531,336£350k£11.17
2 Oct 20234,705£526k£111.72
12 Nov 20214,480£250k£55.86
30 Oct 20204,300£240k£55.86

Officers

Officers

3 active
Status
Herbada, DavidDirectorSpanishEngland553 May 2018Active
Middleton, William JamesDirectorBritish,australianUnited Kingdom433 May 2018Active
Prendergast, Mark ThomasDirectorBritishUnited Arab Emirates615 Jul 2019Active

Shareholders

Shareholders (26)

Mr Heping Zhang
15.7%
23,690
Richard Chenevix-trench
11.1%
16,646

Persons with Significant Control

Persons with Significant Control (0)

No PSC information available

Group Structure

Group Structure

SONOSINE LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
14 Apr 2026Confirmation StatementConfirmation statement made on 14 Apr 2026 with updates
12 Mar 2026OfficersChange to director Mr William James Middleton on 19 Dec 2025
11 Mar 2026CapitalAllotment of shares (GBP 150.414) on 3 Mar 2026
28 Jan 2026OfficersChange to director Mr David Herbada on 28 Jan 2026
28 Jan 2026OfficersChange to director Mr Mark Thomas Prendergast on 28 Jan 2026
14 Apr 2026 Confirmation Statement

Confirmation statement made on 14 Apr 2026 with updates

12 Mar 2026 Officers

Change to director Mr William James Middleton on 19 Dec 2025

11 Mar 2026 Capital

Allotment of shares (GBP 150.414) on 3 Mar 2026

28 Jan 2026 Officers

Change to director Mr David Herbada on 28 Jan 2026

28 Jan 2026 Officers

Change to director Mr Mark Thomas Prendergast on 28 Jan 2026

Recent Activity

Latest Activity

Confirmation statement made on 14 Apr 2026 with updates

1 months ago on 14 Apr 2026

Change to director Mr William James Middleton on 19 Dec 2025

2 months ago on 12 Mar 2026

Allotment of shares (GBP 150.414) on 3 Mar 2026

2 months ago on 11 Mar 2026

Change to director Mr David Herbada on 28 Jan 2026

4 months ago on 28 Jan 2026

Change to director Mr Mark Thomas Prendergast on 28 Jan 2026

4 months ago on 28 Jan 2026